Gide has assisted the banking syndicate made up of Goldman Sachs and SVB Leerink LLC, on the USD 194 million PIPE deal of DBV Technologies, dual listed company on Euronext Paris and the Nasdaq through the offer of 32,855,669 ordinary shares and of 28,276,331 pre-funded warrants.
This fundraising is primarily intended, if approved, to finance a new pivotal Phase 3 study for modified Viaskin Peanut (mVP) called the VITESSE study and activities associated with the potential approval and launch of Viaskin Peanut. It is in line with previous fundraisings (notably in 2019 and 2020) which were intended to finance the preparation of the commercialization of Viaskin®Peanut during which Gide had also assisted the banking syndicate.
Gide acted for the fifth time for the bank syndicate in a capital increase for DBV Technologies with a team headed by partner Arnaud Duhamel, and counsel Guilhem Richard, working with associates Mariléna Gryparis, Mélanie Simon-Giblin and Shanna Kim.
McDermott Will & Emery acted for DBV Technologies with a team headed by partners Emmanuelle Trombe and Bertrand Delafaye, working with associates Lucie Martin, Ludivine Rabreau and Claire Chabat.
Firms Goodwin and Cooley, respectively advising the banks and the issuer, also acted on aspects of US law.